La cadena de opciones muestra datos clave de las opciones de acciones de Biofrontera a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Biofrontera..

Biofrontera (NASDAQ:BFRI) Bolsa, Cadena de Opciones

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Quantum,Computing,Concept,,Quantum,Mechanics,,Advanced,Technology,,Artificial,Intelligence,And

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

HCTI

IXHL

KLRS

LGPS

ORGN

PTIX

QUBT

SATL

SPCE

TSSI

TVTX

Descubre las acciones que destacan en el premercado de EE. UU.: Quantum Computing sube tras superar expectativas, mientras otras caen.

Acciones de Quantum Computing (QUBT) se disparan un 12%; aquí están 20 acciones que se mueven en premercado

Biofrontera Inc

Press Releases

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

News

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

BFRIW

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

Lyra Therapeutics

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

SenesTech

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

VYNE Therapeutics

cbdMD

Benchmark

Comments

Biofrontera

Biofrontera (BFRI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL